Skip to main content

roche-logo

The most interesting aspect of Foundation Medicine (NASDAQ:FMI) is that, last year, cancer giant Roche (OTCQX:RHHBY) paid $50 per share to buy a 56% stake in the company. Bill Gates and Google (NASDAQ:GOOG) (NASDAQ:GOOGL) Ventures are also owners in this genomic testing company. However, right now, the stock is trading at $22.50, about half that Roche number.

Were all these smart people wrong? Did the M&A decision makers at Roche and the analysts working for Bill Gates and Google Ventures not do their homework? Or are we missing something here?

{iframe}http://seekingalpha.com/article/4017652-foundation-medicines-tie-ups-roche-bill-gates-google-ventures-major-value-drivers{/iframe}

Search

You have successfully subscribed to the newsletter

There was an error while trying to send your request. Please try again.

BioHealth Innovation will use the information you provide on this form to be in touch with you and to provide updates and marketing.